tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Icosavax (ICVX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRNResearch Report) and Icosavax (ICVXResearch Report) with bullish sentiments.

BioMarin Pharmaceutical (BMRN)

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $100.00. The company’s shares closed last Friday at $84.25.

According to TipRanks.com, Tewari is a 4-star analyst with an average return of 35.4% and a 56.3% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Zentalis Pharmaceuticals, and Enanta Pharmaceuticals.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $113.36, a 34.6% upside from current levels. In a report issued on January 7, Truist Financial also maintained a Buy rating on the stock with a $135.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Icosavax (ICVX)

In a report issued on January 8, Roger Song from Jefferies maintained a Buy rating on Icosavax, with a price target of $50.00. The company’s shares closed last Friday at $18.09.

According to TipRanks.com, Song has 0 stars on 0-5 stars ranking scale with an average return of -20.5% and a 7.7% success rate. Song covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Inovio Pharmaceuticals, and Aclaris Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Icosavax with a $50.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed